BACKGROUND: Vascular endothelial growth factor (VEGF) is a potent tumour-produced angiogenic factor. In this study serum levels of VEGF were measured before treatment and during follow-up in patients undergoing primary treatment for suspected soft tissue sarcoma (STS) to assess the value of serum VEGF as a tumour marker. METHODS: Between April 2001 and September 2002, serum VEGF levels were analysed prospectively in 144 patients undergoing primary treatment (surgery, 123; cytotoxic chemotherapy, ten; oral imatinib, eight; radiotherapy, three) for suspected soft tissue sarcoma. Serum VEGF was measured by immunoassay before treatment, in the immediate postoperative interval in patients undergoing surgery, and during follow-up. Serum VEGF concentrations were also measured in 15 healthy volunteers. RESULTS: Median pretreatment serum VEGF levels were significantly raised in patients with grade 2 and grade 3 sarcomas compared with concentrations in patients with benign lesions (413 and 467 versus 233 pg/ml respectively; P=0.007 and P=0.003 respectively). In patients with tumours that had a high level of VEGF expression before treatment, follow-up measurements reflected disease status after treatment. CONCLUSION: Serum VEGF expression correlated with grade in soft tissue sarcoma and reflected response to treatment. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
BACKGROUND:Vascular endothelial growth factor (VEGF) is a potent tumour-produced angiogenic factor. In this study serum levels of VEGF were measured before treatment and during follow-up in patients undergoing primary treatment for suspected soft tissue sarcoma (STS) to assess the value of serum VEGF as a tumour marker. METHODS: Between April 2001 and September 2002, serum VEGF levels were analysed prospectively in 144 patients undergoing primary treatment (surgery, 123; cytotoxic chemotherapy, ten; oral imatinib, eight; radiotherapy, three) for suspected soft tissue sarcoma. Serum VEGF was measured by immunoassay before treatment, in the immediate postoperative interval in patients undergoing surgery, and during follow-up. Serum VEGF concentrations were also measured in 15 healthy volunteers. RESULTS: Median pretreatment serum VEGF levels were significantly raised in patients with grade 2 and grade 3 sarcomas compared with concentrations in patients with benign lesions (413 and 467 versus 233 pg/ml respectively; P=0.007 and P=0.003 respectively). In patients with tumours that had a high level of VEGF expression before treatment, follow-up measurements reflected disease status after treatment. CONCLUSION: Serum VEGF expression correlated with grade in soft tissue sarcoma and reflected response to treatment. Copyright 2003 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
Authors: M Agulnik; R L B Costa; M Milhem; A W Rademaker; B C Prunder; D Daniels; B T Rhodes; C Humphreys; S Abbinanti; L Nye; R Cehic; A Polish; C Vintilescu; T McFarland; K Skubitz; S Robinson; S Okuno; B A Van Tine Journal: Ann Oncol Date: 2017-01-01 Impact factor: 32.976
Authors: S Tariq Mahmood; Samuel Agresta; Carlos E Vigil; Xiuhua Zhao; Gang Han; Gina D'Amato; Ciara E Calitri; Michelle Dean; Christopher Garrett; Michael J Schell; Scott Antonia; Alberto Chiappori Journal: Int J Cancer Date: 2011-03-25 Impact factor: 7.396
Authors: Benjamin M Kahn; Alfredo Lucas; Rohan G Alur; Maximillian D Wengyn; Gregory W Schwartz; Jinyang Li; Kathryn Sun; H Carlo Maurer; Kenneth P Olive; Robert B Faryabi; Ben Z Stanger Journal: J Clin Invest Date: 2021-01-19 Impact factor: 14.808
Authors: Thomas K Kilvaer; Andrej Valkov; Sveinung Sorbye; Eivind Smeland; Roy M Bremnes; Lill-Tove Busund; Tom Donnem Journal: PLoS One Date: 2010-12-14 Impact factor: 3.240
Authors: Thomas Brodowicz; Bernadette Liegl-Atzwager; Emmanuelle Tresch; Sophie Taieb; Andrew Kramar; Viktor Gruenwald; Marie Vanseymortier; Stéphanie Clisant; Jean-Yves Blay; Axel Le Cesne; Nicolas Penel Journal: BMC Cancer Date: 2015-03-14 Impact factor: 4.430
Authors: Thomas K Kilvaer; Eivind Smeland; Andrej Valkov; Sveinung W Sorbye; Roy M Bremnes; Lill-Tove Busund; Tom Donnem Journal: BMC Clin Pathol Date: 2014-01-20